CYP3A4 and benign prostatic hyperplasia: It might be that BPH patients harbouring both CYP3A4 and VDRTaqI combined risk genotypes have a higher level of androgen hormones and lower level of calcitriol, which might lead to an increase in prostate cell growth and reduce the level of differentiation and apoptosis, which might result in the occurrence of PRCa.